NOXXON enrolls 1st patient in high dose cohort of clinical trial for brain cancer

Berlin-based leading biotechnology firm- NOXXON Pharma N.V. has recently made it to the headlines following its announcement of enrolling the first patient candidate in the 3rd high dose cohort of the Phase 1/2 clinical trials targeted on treating a newly diagnosed brain cancer.

For the record, NOXXON Pharma is focused on enhancing cancer treatments by targeting tumor microenvironment and the cancer immunity cycle by disrupting tumor protection carrier and blocking tumor repair.

As per credible reports, the study examines three dose regimens of NOX-A12 constituting of 200, 400, and 600 mg per week, each combined with external-beam radiotherapy in the newly detected brain cancer patients who would not be benefitted clinically from the treatment with standard chemotherapy procedures.

Once the enrolled patient in the third cohort has received a 4-week treatment of the dose and radiotherapy, the Data Safety Monitoring Board will organize to determine whether it is safe to recruit the remaining patients in the cohort.

Speaking on the recent move, CEO of NOXXON- Aram Mangasarian cited that as the company looks to enter the last cohort of the dose escalation trial and accumulating sufficient data, it will soon be in a position to undermine the recommended dose of its next controlled, randomized brain cancer trial which would compare NOX-A12 in combination with radiotherapy to standard of care.

Post this, the company plans to recruit additional patients to expand the efficacy and safety data-set. He added that the additional data would provide a comprehensive basis for discussions with US and EU regulators concerning plans for its next trial, which is anticipated to be registrational.

Commenting on other patient recruitment, Aram mentioned that the recruitment into the current trial would continue in the company’s six study centers, three of which are deemed to be added in October 2020 in an attempt to mitigate the challenges faced by the hospital staff as a result of the coronavirus pandemic.

Source Credit: